These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28898162)

  • 1. Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.
    Zwolak A; Armstrong AA; Tam SH; Pardinas JR; Goulet DR; Zheng S; Brosnan K; Emmell E; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017; 9(8):1306-1316. PubMed ID: 28898162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding.
    Zwolak A; Leettola CN; Tam SH; Goulet DR; Derebe MG; Pardinas JR; Zheng S; Decker R; Emmell E; Chiu ML
    Sci Rep; 2017 Nov; 7(1):15521. PubMed ID: 29138497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development.
    Ollier R; Wassmann P; Monney T; Ries Fecourt C; Gn S; C A V; Ayoub D; Stutz C; Gudi GS; Blein S
    MAbs; 2019; 11(8):1464-1478. PubMed ID: 31462177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
    Pollastrini J; Dillon TM; Bondarenko P; Chou RY
    Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin-binding protein-based affinity chromatography in bispecific antibody purification: Functions beyond product capture.
    Li Y
    Protein Expr Purif; 2021 Dec; 188():105976. PubMed ID: 34537355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G.
    Zhou J; Johnson JE; Ghetie V; Ober RJ; Ward ES
    J Mol Biol; 2003 Sep; 332(4):901-13. PubMed ID: 12972260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient process of generating bispecific antibodies via controlled Fab-arm exchange using culture supernatants.
    Paul S; Connor J; Nesspor T; Haytko P; Boakye K; Chiu ML; Jiang H
    Protein Expr Purif; 2016 May; 121():133-40. PubMed ID: 26826313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.
    Tustian AD; Endicott C; Adams B; Mattila J; Bak H
    MAbs; 2016; 8(4):828-38. PubMed ID: 26963837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.
    Deng R; Meng YG; Hoyte K; Lutman J; Lu Y; Iyer S; DeForge LE; Theil FP; Fielder PJ; Prabhu S
    MAbs; 2012; 4(1):101-9. PubMed ID: 22327433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.